SRTD Biotech GmbH

We are developing the first pro-drug platform on RNA level, targeting oncological, viral and genetic diseases.

It is our mission to open a new chapter in treating diseases and to deliver so called selectively expressed RNAs (seRNAs) to patients. We have an ambitious pipeline that targets indications of highest medical need. Many devastating diseases cannot be effectively treated. Even if therapies exist, often they don’t specifically target the diseased area, leading to a high risk of severe side effects. To overcome this inherent problem, we have developed seRNA as a new RNA-based therapy approach.